Industry News

Search Articles:

Omeros discovers new cancer-immunity pathways controlled by GPR174
Omeros announced a new approach to cancer immunotherapy that targets inhibition of GPR174, a member of the family of G protein-coupled receptors, which can be combined with and significantly improve the tumor-killing effects of adenosine pathway inhibitors.September 10, 2019